As of May 23, 2025, Taxus Pharmaceuticals Holdings Inc (TXSP) reports a ROE (Return on Equity) of 218.04%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Taxus Pharmaceuticals Holdings Inc's ROE (Return on Equity)
Over recent years, Taxus Pharmaceuticals Holdings Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2017-06-30 | 218.04% |
| 2016-06-30 | 2235.45% |
| 2015-06-30 | -1026.74% |
| 2014-06-30 | 493.33% |
| 2013-06-30 | -244.20% |
This fluctuation highlights how Taxus Pharmaceuticals Holdings Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Taxus Pharmaceuticals Holdings Inc's ROE (Return on Equity) to Peers
To better understand Taxus Pharmaceuticals Holdings Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Taxus Pharmaceuticals Holdings Inc (TXSP) | 218.04% |
| Indigo Books and Music Inc (IDG.TO) | 248.00% |
| DAVIDsTEA Inc (DTEA) | 161.70% |
| Ulta Beauty Inc (ULTA) | 48.27% |
| Build-A-Bear Workshop Inc (BBW) | 37.23% |
| Hibbett Inc (HIBB) | 24.62% |
Compared to its competitors, Taxus Pharmaceuticals Holdings Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.